These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 6542067)
1. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice. Katano M; Irie RF Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067 [TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft. Katano M; Jien M; Irie RF Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688 [TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibody to tumor-associated ganglioside GD2. Katano M; Saxton RE; Irie RF J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419 [TBL] [Abstract][Full Text] [Related]
4. Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft. Katano M; Saxton RE; Tsuchida T; Irie RF Jpn J Cancer Res; 1986 Jun; 77(6):584-94. PubMed ID: 3089993 [TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection of human melanoma tumor xenografts with human monoclonal antibodies. Gomibuchi M; Saxton RE; Lake RR; Katano M; Irie RF Int J Rad Appl Instrum B; 1986; 13(1):13-9. PubMed ID: 3771234 [TBL] [Abstract][Full Text] [Related]
6. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687 [TBL] [Abstract][Full Text] [Related]
7. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881 [TBL] [Abstract][Full Text] [Related]
8. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
9. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma. Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494 [TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Cheung NK; Canete A; Cheung IY; Ye JN; Liu C Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225 [TBL] [Abstract][Full Text] [Related]
11. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876 [TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Honsik CJ; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017 [TBL] [Abstract][Full Text] [Related]
13. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201 [TBL] [Abstract][Full Text] [Related]
14. Biodistribution study of murine monoclonal anti-GD3 antibody in nude mice bearing human melanoma xenografts for development of immunoscintigraphy. Ojima F; Ido T; Kijima-Suda I; Nakagawa Y Tohoku J Exp Med; 1998 Jun; 185(2):89-100. PubMed ID: 9747648 [TBL] [Abstract][Full Text] [Related]
15. Recombinant antibodies against ganglioside expressed on tumor cells. Hanai N; Nakamura K; Shitara K Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141 [TBL] [Abstract][Full Text] [Related]
16. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333 [TBL] [Abstract][Full Text] [Related]
19. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849 [TBL] [Abstract][Full Text] [Related]
20. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee MB J Immunother; 1998 Jan; 21(1):75-83. PubMed ID: 9456440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]